Company profile for AviadoBio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AviadoBio our mission is to transform the lives of patients living with neurodegenerative disorders. We are developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases inc...
AviadoBio our mission is to transform the lives of patients living with neurodegenerative disorders. We are developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
86 Hatton Garden Fifth Floor London EC1N 8QQ
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/deals/aviadobio-looks-to-china-for-eye-based-gene-therapy-in-413m-ugenex-pact

BIOSPACE
10 Oct 2025

https://www.fiercebiotech.com/biotech/aviadobio-secures-option-rare-eye-disease-gene-therapy-could-bring-chinese-biotech-413m

FIERCE BIOTECH
09 Oct 2025

https://www.businesswire.com/news/home/20251009502471/en/AviadoBio-and-UgeneX-Therapeutics-Announce-Exclusive-Option-License-Agreement-to-Develop-Next-Generation-Optogenetics-Gene-Therapy-to-Restore-Vision-in-Patients-with-Retinal-Disease

BUSINESSWIRE
09 Oct 2025

https://www.businesswire.com/news/home/20250515426050/en/AviadoBio-Announces-ASPIRE-FTD-Phase-12-Clinical-Trial-in-the-UK-at-Cambridge-University-Hospitals-NHS-Foundation-Trust-Cardiff-and-Vale-University-Health-Board-and-University-College-London

BUSINESSWIRE
15 May 2025

https://www.businesswire.com/news/home/20250430210045/en/AviadoBio-Announces-Completion-of-Second-Cohort-in-Phase-12-ASPIRE-FTD-Clinical-Trial-Studying-AVB-101-for-FTD-GRN

BUSINESSWIRE
01 May 2025

https://www.fiercebiotech.com/biotech/astellas-pays-50m-option-aviadobios-dementia-gene-therapy

FIERCE BIOTECH
08 Oct 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty